Evgen Pharma Plc (EVG)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Evgen Pharma Plc (EVG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013382
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Evgen Pharma Plc (Evgen Pharma), formerly Evgen Pharma Ltd is a drug discovery company that develops medicines to treat cancer and neurological diseases. The company uses sulforadex technology that synthesizes and concurrently stabilizes the naturally occurring compound such as sulforaphane. It carries out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. Evgen Pharma also undertakes clinical plans in oncology in patients with ER+ metastatic breast cancer. The company’s SFX-01 is a patented composition of the synthetic sulforaphane and alpha-cyclodextrin and has completed phase I clinical trials, and others. Evgen Pharma is headquartered in Wilmslow, the UK.

Evgen Pharma Plc (EVG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Evgen Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Evgen Pharma Raises USD3.1 Million Financing 10
Evgen Raises US$0.72 Million In Series B Financing 11
Evgen Secures Series A Financing 12
Licensing Agreements 13
Evgen Pharma Exercises Option for Licensing Agreement with CSIC and University of Seville 13
Evgen Exercises Option for Licensing Agreement with PharmAgra and Lalilab for Sulforade 14
Equity Offering 15
Evgen Pharma Raises USD11 Million in IPO 15
Evgen Pharma Plc – Key Competitors 16
Evgen Pharma Plc – Key Employees 17
Evgen Pharma Plc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
Jun 13, 2017: Evgen Pharma Announces Final Results for the year ended 31 March 2017 19
Dec 05, 2016: Evgen Pharma: Interim results for the six months ended 30 September 2016 20
May 31, 2016: Evgen Pharma Announces Final Results for the year ended 31 March 2016 21
Corporate Communications 25
Apr 03, 2017: Evgen Pharma Announces Directorate Change 25
Jan 17, 2017: Evgen Pharma: Appointment of CFO and Head of Clinical Operations 26
Jan 04, 2016: Evgen Pharma Appoints Chief Medical Officer 27
Clinical Trials 28
Sep 15, 2016: Update re SFX-01 Data at ECTRIMS 2016 28
Sep 08, 2016: Evgen Pharma Announces Presentation of SFX-01 Data at ECTRIMS 2016 29
Aug 24, 2016: Evgen Pharma Announces Orphan Designation in the USA in Subarachnoid Haemorrhage 30
Aug 17, 2016: Evgen Pharma: Clinical Trial Approval for Phase II Study in Breast Cancer 31
May 03, 2016: Evgen Pharma: First Patient Dosed in Phase II Clinical Trial in SAH 33
Mar 02, 2016: Approval of Phase II Clinical Trial in SAH 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Evgen Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Evgen Pharma Plc, Deals By Therapy Area, 2011 to YTD 2017 8
Evgen Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Evgen Pharma Raises USD3.1 Million Financing 10
Evgen Raises US$0.72 Million In Series B Financing 11
Evgen Secures Series A Financing 12
Evgen Pharma Exercises Option for Licensing Agreement with CSIC and University of Seville 13
Evgen Exercises Option for Licensing Agreement with PharmAgra and Lalilab for Sulforade 14
Evgen Pharma Raises USD11 Million in IPO 15
Evgen Pharma Plc, Key Competitors 16
Evgen Pharma Plc, Key Employees 17
Evgen Pharma Plc, Other Locations 18

★海外企業調査レポート[Evgen Pharma Plc (EVG)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Northern Trust Corporation:企業のM&A・事業提携・投資動向
    Northern Trust Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Northern Trust Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • PLx Pharma Inc (PLXP):製薬・医療:M&Aディール及び事業提携情報
    Summary PLx Pharma Inc (PLx Pharma) is a pharmaceutical company that develops patent-protected delivery systems. The company offers products such as PLxGuard delivery system, PLxGuard pipeline products, and PL1100 and PL1200 ibuprofen products. Its PLxGuard delivery system are used in enhancement of …
  • MAEC-Kazatomprom LLP:企業の戦略的SWOT分析
    MAEC-Kazatomprom LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Platinum Group Metals Ltd (PTM):企業の財務・戦略的SWOT分析
    Platinum Group Metals Ltd (PTM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Bangladesh Power Development Board:企業の戦略的SWOT分析
    Bangladesh Power Development Board - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Soitec SA (SOI):企業の財務・戦略的SWOT分析
    Soitec SA (SOI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Swadeshi Industrial Works Plc:企業の戦略・SWOT・財務分析
    Swadeshi Industrial Works Plc - Strategy, SWOT and Corporate Finance Report Summary Swadeshi Industrial Works Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Schlumberger Ltd (SLB):企業の財務・戦略的SWOT分析
    Schlumberger Ltd (SLB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Ebiquity plc (EBQ):企業の財務・戦略的SWOT分析
    Summary Ebiquity plc (Ebiquity) is a marketing and media consultancy service provider. The company’s services include marketing performance optimization services, media value measurement and market intelligence. Its business areas comprise data analytics and advanced analytics. Ebiquity’s data analy …
  • Ghella SpA:企業の戦略・SWOT・財務情報
    Ghella SpA - Strategy, SWOT and Corporate Finance Report Summary Ghella SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Orexigen Therapeutics Inc (OREX)-製薬・医療分野:企業M&A・提携分析
    Summary Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is FDA approved as an adjunct to a reduced-calorie diet and increased …
  • Tulip Oil Holding BV:石油・ガス:M&Aディール及び事業提携情報
    Summary Tulip Oil Holding BV (Tulip Oil) is an upstream oil and gas development and production company that explores and develops undeveloped oil and gas field discoveries. The company's activities include redeveloping abandoned or mature onshore oil and gas ?elds, developing onshore stranded oil an …
  • DTE Energy Co (DTE):企業の財務・戦略的SWOT分析
    DTE Energy Co (DTE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • CIC Insurance Group Limited (CIC):企業の財務・戦略的SWOT分析
    CIC Insurance Group Limited (CIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Merz Aesthetics Inc:企業の戦略的SWOT分析
    Merz Aesthetics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • International SOS Pte Ltd:企業の戦略的SWOT分析
    International SOS Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • CNOOC Ltd (883)-エネルギー分野:企業M&A・提携分析
    Summary CNOOC Limited (CNOOC) is an upstream oil and gas exploration and production company. It engages in exploration, development, production and sale of crude oil and natural gas. In offshore China, the company engages in oil and natural gas exploration, development and production in Bohai, Weste …
  • The Toyama Bank, Ltd.:企業の戦略・SWOT・財務情報
    The Toyama Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Toyama Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • UGL Ltd:企業の戦略的SWOT分析
    UGL Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • PowerSouth Energy Cooperative:企業の戦略的SWOT分析
    PowerSouth Energy Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆